Iterum Therapeutics plc announced that the first patient has been dosed in its Phase 3 clinical trial, known as REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales (REASSURE), comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin(R) (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTI).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.52 USD | -1.94% | -4.40% | -22.84% |
05-10 | Iterum Therapeutics plc Announces Executive Changes | CI |
04-29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.84% | 25.16M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections